The estimated Net Worth of Gary Cantrell is at least $577 Tausend dollars as of 27 February 2017. Mr. Cantrell owns over 37,083 units of Aytu BioPharma Inc stock worth over $339,894 and over the last 8 years he sold AYTU stock worth over $0. In addition, he makes $236,725 as Independent Director at Aytu BioPharma Inc.
Gary has made over 2 trades of the Aytu BioPharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 37,083 units of AYTU stock worth $27,812 on 27 February 2017.
The largest trade he's ever made was exercising 37,083 units of Aytu BioPharma Inc stock on 27 February 2017 worth over $27,812. On average, Gary trades about 7,824 units every 13 days since 2016. As of 27 February 2017 he still owns at least 135,416 units of Aytu BioPharma Inc stock.
You can see the complete history of Mr. Cantrell stock trades at the bottom of the page.
Gary V. Cantrell serves as Independent Director of the Company. Mr. Gary Cantrell joined our Board of Directors in July 2016. He has 30 years of experience in the life sciences industry ranging from clinical experience as a respiratory therapist to his current consulting role with Mayne Pharma Group Limited (“Mayne”) (ASX: MYX) as Business Development Executive focused on acquiring branded prescription assets for Mayne’s U.S. Specialty Brands Division, a position he has held since July 2015. Mr. Cantrell served as CEO of Yasoo Health Inc. (“Yasoo”), a global specialty nutritional company from 2007 through June 2016, highlighted by the sale of its majority asset AquADEKs to Actavis Generics in March 2016. Previously, he was President of The Catevo Group, a U.S.-based healthcare consulting firm. Prior to that, he was Executive Vice President, Sales and Marketing for TEAMM Pharmaceuticals Inc., an Accentia Biopharmaceuticals company, where he led all commercial activities for a public specialty pharmaceutical business. His previous 22 years were at GlaxoSmithKline plc where he held progressively senior management positions in sales, marketing and business development. Mr. Cantrell is a graduate of Wichita State University and serves as an advisor to several emerging life science companies. He served as a director for Yasoo Health Inc., Yasoo Health Limited and Flexible Stenting Solutions, Inc., a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, which was sold to Cordis, while a Division of Johnson & Johnson in March 2013. Mr. Cantrell served as a director of Vyrix from February 2014 to April 2015. Mr. Cantrell’s experience in consulting and executive management within the pharmaceutical industry led to the conclusion that he should serve as a director of our Company in light of our business and structure.
As the Independent Director of Aytu BioPharma Inc, the total compensation of Gary Cantrell at Aytu BioPharma Inc is $236,725. There are 7 executives at Aytu BioPharma Inc getting paid more, with Joshua Disbrow having the highest compensation of $1,043,700.
Gary Cantrell is 64, he's been the Independent Director of Aytu BioPharma Inc since 2016. There are 1 older and 10 younger executives at Aytu BioPharma Inc. The oldest executive at Aytu BioPharma Inc is Michael Macaluso, 67, who is the Independent Director.
Gary's mailing address filed with the SEC is C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD, CO, 80112.
Over the last 9 years, insiders at Aytu BioPharma Inc have traded over $40,722,795 worth of Aytu BioPharma Inc stock and bought 8,465,326 units worth $11,497,374 . The most active insiders traders include Capital, Llc Armistice Capi..., Carl Dockery und Joshua R. Disbrow. On average, Aytu BioPharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,701,531. The most recent stock trade was executed by Greg Pyszczymuka on 30 June 2024, trading 208 units of AYTU stock currently worth $522.
aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.
Aytu BioPharma Inc executives and other stock owners filed with the SEC include: